INNOVATING BIOLOGY
EVerse Biotechnology:
reprogramming agriculture with Bacterial Extracellular Vesicles
What we do:
EVerse Biotechnology is an ag-tech startup pioneering the use of extracellular vesicles (EVs) in agriculture, unlocking a new generation of precision biological solutions with applications across biotechnology and human health.
THE PROBLEM WITH CONVENTIONAL AGRICULTURE
Current Challenges
Increasing resistance to chemical pesticides
→ Reduced efficacy against key pests (e.g., soybean pests).
Environmental impact
→ Soil degradation, water contamination, biodiversity loss.
Regulatory pressure
→ Restrictions on agrochemicals worldwide.
Non-specific toxicity
→ Harm to beneficial organisms (pollinators, microbiota).
Rising costs for farmers
→ More applications needed for the same effect.
Figures are for illustrative purposes only
Our Vision
To replace conventional agrochemicals through extracellular vesicle-based technologies, enabling precise, sustainable, and biologically derived agricultural solutions.
Technology
Bacterial extracellular vesicles as a delivery platform
Bacterial extracellular vesicles (bEVs) are nano-sized particles naturally released by bacteria.
These vesicles act as highly efficient delivery systems, transporting proteins, metabolites, lipids, and nucleic acids.
At EVerse, we engineer and harness bEVs as programmable biological carriers that deliver functional molecules directly to plants, insects, and microbial pathogens.
Key Features:
-
Natural and biocompatible nano-carriers;
-
Protection and stabilization of sensitive cargo;
-
Efficient delivery across biological barriers;
-
Scalable production through microbial fermentation;
-
Reduced environmental impact compared to chemical inputs.
Transmission electron microscopy (TEM) image of a bacterial cell and associated extracellular vesicles (EVs). The image illustrates the release of bEVs into the extracellular environment, highlighting their natural production and potential role as biological delivery systems. Image acquired by Getulio Oliveira, PhD (EVerse Biotechnology), unpublished data.
Why bEVs Outperform Whole Bacterial Cells as biologicals
Comparison whole bacterial cells vs bEVs
Whole Bacterial Cells (Conventional biologicals)
-
Living organisms → unpredictable behavior in the field
-
Depend on survival, colonization, and environmental conditions
-
Delayed mode of action (require growth and metabolite production)
-
Risk of ecological imbalance and horizontal gene transfer
-
More complex and slower regulatory approval pathways
bEVs (EVerse Technology)
-
Cell-free system → highly controlled and reproducible, do not require survival or colonization
-
Pre-loaded with defined bioactive cargo (proteins, metabolites, RNA)
-
Non-replicative → improved biosafety profile
-
More stable and easier to formulate and store
-
Potentially simplified regulatory pathway
Figures are for illustrative purposes only
Ongoing Projects
Advancing bacterial extracellular vesicle technologies for next-generation agricultural solutions
-
Bacterial extracellular vesicles (bEV)-based control of soybean pest (Euschistus heros)
Development of bacterial extracellular vesicle (bEV)-based bioinsecticides targeting the neotropical brown stink bug, a major pest impacting soybean production in Latin America.
🟢 Patent pending
-
bEVs for Lepidopteran pest control
Exploration of bEV-mediated delivery of insecticidal molecules targeting key Lepidopteran pests affecting major crops.
🟡 Early-stage development
-
bEV-based strategies for Dipteran pest control
Development of bEV-based platforms targeting Dipteran species, including agricultural and human-relevant insect pests.
🟡 Early-stage development
-
bEV-mediated delivery of ssDNA against Xanthomonas spp.
Engineering bacterial extracellular vesicles for the delivery of single-stranded DNA (ssDNA) to control Xanthomonas spp., a major bacterial pathogen affecting tomato and other crops.
🟡 Early-stage development
Survival analysis of Euschistus heros following treatment with bEV. bEV-treated insects show reduced survival compared to control, supporting the potential of bEVs as effective bioinsecticidal agents. Representative data generated by Getulio Oliveira (unpublished; included in ongoing patent filings and manuscript preparation).
TEAM
Founder and CEO
Getulio Oliveira, PhD, is the Founder and CEO of EVerse, a biotechnology company focused on developing extracellular vesicle-based solutions for agriculture and human health.
Dr. Oliveira has over 15 years of experience in extracellular vesicle research, with expertise spanning molecular biology, proteomics, nanotechnology, and advanced vesicle characterization.
He completed his postdoctoral training at Beth Israel Deaconess Medical Center, Harvard Medical School, where he worked on cutting-edge EV technologies.
He has collaborated with leading institutions, including Harvard Medical School, Massachusetts General Hospital, Northeastern University, and industry partners in biotechnology, contributing to the development of innovative EV-based platforms.
He is currently developing his research at the Universidade Católica de Brasília, Brazil, focusing on translating extracellular vesicle science into scalable and impactful biotechnological applications.
His work bridges fundamental science and translational applications, with a focus on scalable and impactful biotechnologies.
Profiles & Publications
Partners and collaborators
CONTACT
e-mail:
LinkedIn:
Call to Action:
Interested in partnerships, collaborations, or investment opportunities?
Connect with us to explore how we can accelerate the development and commercialization of extracellular vesicle-based solutions together.